Gerresheimer's June Deadline: A Test of Survival Amid Accounting Turmoil

German pharma packaging firm fights for survival, negotiating with banks after SDAX delisting and BaFin probe over €291M in accounting issues.

For Gerresheimer, the clock is ticking down to a single, critical month. The German pharmaceutical packaging supplier, ejected from the SDAX index on April 10, 2026, faces a convergence of crises that will reach a decisive point in June. With its financial calendar frozen and regulators circling, the company's immediate future hinges on delivering an audited annual report and securing its financial lifelines.

The depth of the accounting scandal is still being plumbed. What began with prematurely booked revenues under so-called bill-and-hold agreements has expanded significantly. Germany's financial watchdog, BaFin, opened a formal probe on March 6, targeting specific balance sheet items. These include potentially misstated leasing liabilities of EUR 65.5 million, incorrectly stated useful lives of capitalized development costs with a book value of EUR 29.4 million, and improperly recorded impairments in the Advanced Technologies segment, valued at EUR 196.5 million.

This regulatory scrutiny has paralyzed the company's reporting. The publication of first-quarter figures and the annual general meeting scheduled for June have been postponed indefinitely. The failure to file an audited 2025 annual report directly triggered the removal from the SDAX, a move that compounds the selling pressure on a stock already in freefall. Since the start of the year, Gerresheimer's shares have plummeted approximately 38 percent, recently trading around EUR 17.17.

In a parallel development, the auditor at the center of the storm is also under investigation. The audit oversight body APAS has initiated professional misconduct proceedings against KPMG. The accusation is that the firm issued an unqualified audit opinion on the 2024 financial statements despite systematic errors in revenue recognition—ironically, in KPMG's first year as auditor after replacing Deloitte.

To shore up its strained balance sheet, Gerresheimer's management is racing to sell assets. The divestment of its US subsidiary Centor Inc., which specializes in packaging systems for prescription drugs, is already underway, with Morgan Stanley advising on a deal targeted for completion this year. The company is also moving to separate its Moulded Glass business, though a formal sales process for that unit will begin at a later date. These moves are accompanied by substantial, non-cash impairment charges estimated between EUR 220 and EUR 240 million. Operationally, the company will shutter its Moulded Glass plant in Chicago Heights by the end of 2026.

The urgency stems from a technical default. Gerresheimer has violated contractual reporting obligations to its lenders, forcing management into critical negotiations to secure waivers and extensions on its credit facilities. The company's confirmed revenue forecast for 2026 of EUR 2.3 to EUR 2.4 billion is explicitly conditional on these bank talks succeeding and on resolving the BaFin's objections.

Amid the uncertainty, some institutional investors see a contrarian opportunity. Firms including Deka Investment and CastleKnight have recently reported building new positions, betting the severely depressed valuation presents an entry point. Market speculation also briefly flared in March after Reuters reported interest from US packaging giant Silgan Holdings, with talk of a potential EUR 41 per share offer, though those discussions were described as preliminary with no official comment from either side.

All roads now lead to June 2026. By then, Gerresheimer must present its audited 2025 financial statements and demonstrate progress in stabilizing its finances. Success would provide investors with their first reliable fundamental footing in months. Another delay, however, would intensify the pressure on a stock and a company already pushed to the brink. The next tangible update on its precarious position is scheduled for the half-year report on July 14, 2026.